Chronic Inflammatory Demyelinating Polyneuropathy: Pathophysiology, Diagnosis, and New and Emerging Treatment Options
Saturday, September 13th from 8:30am - 9:20am EDT
Name
*
First Name
Last Name
Credentials:
State Licensed to Practice in:
Email
*
example@example.com
1. A diagnosis of CIDP can be confidently made if:
*
a. CSF protein is elevated, numbness and pain are present in the hands and feet, and axon loss is present on nerve conduction studies
b. Numbness is present in the feet, balance is unsteady, and nerve conduction studies show demyelinating changes
c. Weakness and numbness are present in the arms and legs, and nerve conduction studies show demyelinating changes
d. Numbness is present in the arms and legs, nerve conduction studies show axonal changes, and a patient reports feeling better after treatment with IVIG
2. The pathophysiologic process of CIDP:
*
a. Likely involves IgG antibodies, however no pathogenic antibody can be demonstrated in most patients
b. Is driven by a combination of T cell activation and targeted antibodies, which can be confirmed in most patients
c. Does not involve activation of the complement cascade in most patients
d. Is usually triggered by an external event, such as an infection
3. In the ADHERE Trial:
*
a. Patients were rarely found to not have CIDP by the adjudication panel
b. Before entering Stage A open label, only patients that were treatment naïve or off treatments needed to demonstrate response to standard therapies (such as IVIG or corticosteroids)
c. In Stage A, efgartigimod was administered subcutaneously once per week, but in Stage B, administration was every 2nd or 3rd week depending on clinical outcomes
d. Most patients improved in the open label Stage A portion of the study and did not relapse in the Stage B randomized portion of the trial
Overall Activity Feedback
Please rate the extent to which this activity met the following objectives:
Learning Objectives
Rows
Poor
Fair
Good
Very Good
Excellent
Review the pathophysiology and disease burden of CIDP, the role of IgG autoantibodies, accurate patient identification and diagnosis, and the limitations of current treatments.
Analyze recent clinical trial data on new and emerging biologic treatments for CIDP and be prepared to contextualize these data into their practices.
Develop individualized treatment plans for CIDP based on patient prognosis, a review of treatment options, an assessment of safety, familiarity with current treatment guidelines, and shared decision making.
Please provide us with feedback regarding your experience at the activity:
Rows
Poor
Fair
Good
Very Good
Excellent
Overall Program
Content
Usefulness
Please rate the faculty on their overall teaching ability:
Rows
Poor
Fair
Good
Very Good
Excellent
Sudhir Athni, MD
Do you feel this activity was fair balanced and free of commercial bias?
Yes
No
If no, please explain:
This educational activity will result in a change in my role as a healthcare team member.
Yes
No
N/A
Based on your participation in this activity, choose the statement(s) that applies to how your role as a healthcare team member will change
I gained new strategies/skills/information that my team can apply to practice
I plan to implement new strategies/skills/information in my practice
I will be more competent in my team’s management of patient care
I will improve my communication with the healthcare team
What factors beyond clinical care that effect the health of your patients does your team experience?
Date
-
Month
-
Day
Year
2 digit month, 2 digit day, 4 digit year
Date
I participated in this activity and claim _______ credit(s).
*
Attestation:
This activity is certified for a maximum of 1.0 AMA PRA Category 1 Credits™.
Submit
Should be Empty: